Tuesday, Boston Scientific Corporation (NYSE:BSX) agreed to acquire Silk Road Medical Inc (NASDAQ:SILK) for $27.50 in cash per share, representing an equity value of approximately $1.26 billion.
The per-share price represents an approximate 38% premium to the volume-weighted average share price of Silk Road Medical's common stock over the past 60 days.
Related: Heart Devices Focused Silk Road Medical Stock Gets an Upgrade – Analyst Says New CEO's Initiatives Sets Stage For 'Back On Track'
Silk Road Medical is a minimally invasive medical device company for carotid artery procedures.
The acquisition adds technology for stroke prevention to Boston Scientific's vascular portfolio.
The TCAR system gained FDA approval in 2015 and is supported by several clinical studies demonstrating a reduced risk of stroke and other complications associated with traditional open surgery.
The products sold by Silk Road Medical are the only devices commercially available for use during the TCAR procedure.
"The TCAR platform developed by Silk Road Medical is a notable advancement in the field of vascular medicine, which has revolutionized stroke prevention and the treatment of carotid artery disease," said Cat Jennings, president of Vascular, Peripheral Interventions, Boston Scientific.
The Silk Road board of directors has unanimously approved the transaction and recommended that Silk Road stockholders adopt the merger agreement.
The transaction is expected to close in the second half of 2024.
Upon the completion of the transaction, Silk Road will become a wholly-owned subsidiary of Boston Scientific.
Silk Road Medical has guided to net revenue of approximately $194-198 million in 2024, representing 10-12% growth over the prior fiscal year.
The impact to Boston Scientific adjusted earnings per share is expected to be immaterial in 2024 and 2025 and accretive thereafter.
Boston Scientific expects the impact to GAAP earnings per share to be less accretive or dilutive, as the case may be, due to amortization expense and acquisition-related net charges.
Price Action: SILK shares are up 23.8% at $26.83, and BSX stock is down 0.64% at $75.70 at last check Tuesday.
Photo via Shutterstock
週二，波士頓科學公司（NYSE:BSX）同意以每股27.50美元的現金收購silk road medical股份（NASDAQ:SILK），相當於大約12.6億美元的股權價值。
每股價格相當於過去60天silk road medical普通股的成交量加權平均價格溢價約38%。
相關新聞: 吉利德的 Trodelvy 在普通膀胱癌最常見類型的後期研究中未能達到主要目標。心臟器械專注的silk road medical股票得到升級-分析師表示，新CEO的倡議爲"回到正軌"鋪平了道路。
SILK ROAD MEDICAL是一家小創傷醫療器械公司，爲頸動脈手術提供設備。
此次收購將爲波士頓科學的血管產品組合增添中風預防技術。
TCAR系統於2015年獲得FDA批准，並得到多項臨床研究的支持，證明了與傳統開放手術相比，它能夠降低中風和其他併發症的風險。
silk road medical銷售的產品是唯一商業上可用於TCAR手術的設備。
波士頓科學的血管和外圍干預部門總裁Cat Jennings表示:"silk road medical開發的TCAR平台是血管醫學領域的一項顯着進展，它革新了中風預防和頸動脈疾病的治療。"
silk road medical董事會已一致批准交易，並建議silk road股東採納合併協議。
交易預計將在2024年下半年完成。
交易完成後，silk road將成爲波士頓科學的全資子公司。
silk road medical預計2024年的淨收入約爲1.94-1.98億美元，較上個財年增長10-12%。
波士頓科學調整後每股收益預計在2024年和2025年不會受到影響，在此之後將具有增值作用。
由於攤銷費用和收購相關淨費用等，波士頓科學預期對普通會計原則淨收益每股影響較小。
